Quarterly report pursuant to Section 13 or 15(d)

Recent Developments, Liquidity and Management???s Plans (Details Narrative)

v3.22.2.2
Recent Developments, Liquidity and Management’s Plans (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 16, 2022
Apr. 16, 2021
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Dec. 31, 2020
Mar. 23, 2020
Goodwill     $ 10,498,539       $ 10,498,539   $ 10,498,539    
Cash on hand     1,115,174       1,115,174   555,967    
Marketable securities     4,505,825       4,505,825   11,003,071    
Loss from operations     3,636,043   $ 18,092,336   7,758,077 $ 21,182,040      
Working capital     4,089,352       4,089,352        
Stockholders' equity     16,118,343 $ 19,622,140 31,074,335 $ (8,346,738) 16,118,343 31,074,335 23,647,174 $ (5,257,034)  
Accumulated deficit     86,319,645       86,319,645   78,561,568    
Net cash provided by operating activities             5,934,245 8,258,496      
Net loss     $ 3,636,043 $ 4,122,034 $ 18,092,336 $ 3,089,704 7,758,077 21,182,040      
Increase in trade and other payables             $ 1,854,909 $ (1,988,204)      
Contribution Agreement [Member] | Premas Biotech PVT Ltd [Member]                      
Amount owed on investments                 1,500,000    
Payments to investments                 $ 1,200,000    
Merger Agreement [Member]                      
Issuance of post reverse stock split   28,553,307                  
Exchange ratio percentage   77.05%                  
Percentage of common stock 49.68%                    
Merger Agreement [Member] | Pre-funded Warrants [Member]                      
Warrants to purchase   986,486                  
Cystron Biotech LLC [Member] | Membership Interest Purchase Agreement [Member]                      
Acquired membership interests, percentage                     100.00%
MYMD Pharmaceuticals, Inc., [Member] | Merger Agreement [Member]                      
Business acquisition description   Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger.                  
Akers Biosciences, Inc [Member]                      
Goodwill   $ 10,498,539                  
Pre market capitalization   42,477,346                  
Tangible asset   $ 31,978,807                  
Common shares outstanding   8,335,627                  
Akers Biosciences, Inc [Member] | Restricted Stock Units (RSUs) [Member]                      
Vested restricted stock unit   263,026                  
Fair market value price per share   $ 4.94